Home
/

What is a CRP-to-Lymphocyte Ratio Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

The CRP-to-Lymphocyte Ratio (CLR) combines CRP—a liver-produced inflammatory marker driven by IL-6—with circulating lymphocyte counts to balance inflammatory drive against immune reserve. A low ratio reflects health; elevation is associated with acute infection, tissue injury, autoimmune flares, or sepsis and may help support outcome prediction in respiratory infections, surgery, and cancer when tracked alongside CBC differential and procalcitonin.

Read more →
Table of contents

Innate inflammation and adaptive immunity, joined in one index

The CRP-to-lymphocyte ratio (CLR) is a composite blood marker built from two routine measures: C‑reactive protein and the circulating lymphocyte count. CRP is a soluble protein made by the liver (hepatocytes) when pro‑inflammatory cytokines, especially interleukin‑6, trigger the acute-phase response. Lymphocytes are white blood cells of the adaptive immune system (T cells, B cells, and NK cells). They develop from bone marrow precursors and recirculate between blood, lymph, and lymphoid tissues. Combining these two pieces yields a single index of inflammation and immune cell status.

This ratio captures the interplay between innate inflammation and adaptive immune capacity in real time. CRP climbs quickly when tissues are injured or infected, signaling systemic inflammatory drive. Lymphocyte numbers shift as the immune system redistributes and activates cells to meet demand. Together, the ratio summarizes how strong the inflammatory signal is relative to the available lymphocyte pool. In practical terms, it offers a compact snapshot of the host response—integrating acute-phase activity with immune readiness—during physiological stress, infection, or recovery (innate–adaptive crosstalk).

Inflammatory drive against immune reserve

The CRP-to-lymphocyte ratio (CLR) combines two complementary signals: C-reactive protein from the liver, which rises with innate inflammation, and circulating lymphocytes, which reflect adaptive immune capacity. By balancing "inflammatory drive" against "immune reserve," CLR offers a snapshot of systemic stress on the cardiovascular, metabolic, and infection-defense networks.

It captures the balance between inflammatory burden and immune reserve. At a systems level, this ratio tracks how much energy is being diverted to inflammation versus maintenance, with implications for vascular tone, insulin signaling, infection resilience, wound repair, cognition, and reproductive function.

When CLR sits low and what pushes it higher

There is no universal reference range, but in healthy states the ratio sits low; within reference ranges values tend toward the lower end. Typical values are low-to-mid when CRP is low and lymphocytes are normal. Children, who naturally have higher lymphocyte counts, often show lower ratios. Pregnancy and higher adiposity can nudge the ratio upward via modest CRP increases, and aging may raise it through lymphocyte decline.

When the ratio is low, it usually signals quiet inflammation and a well-supplied adaptive immune system, with steady energy and predictable recovery from everyday stressors. Rarely, very low values reflect unusually high lymphocyte counts during certain viral illnesses or lymphoid disorders, sometimes accompanied by fatigue, swollen lymph nodes, or night sweats.

Low values usually reflect a quiet inflammatory state with adequate or higher lymphocyte availability. This pattern aligns with efficient vascular and metabolic function and resilient immune surveillance. It can also occur with lymphocytosis (for example, some viral infections or hematologic conditions) or with impaired CRP production in advanced liver disease, so context matters.

Being in range suggests balanced inflammatory signaling and intact adaptive immunity, supporting stable endothelial function, glucose handling, and recovery capacity. Research generally links lower values within the normal range to more favorable cardiometabolic and infectious risk profiles, though exact cut-points vary across studies and labs.

When the ratio is high, CRP is elevated, lymphocytes are reduced, or both. This pattern appears with acute bacterial infection, tissue injury, autoimmune flare, active atherosclerosis, or severe stress states like sepsis. Fever, aching, and profound tiredness are common; lymphopenia adds susceptibility to infections. Older adults are more prone; pregnancy-related CRP rises can raise the ratio, though marked elevations may track complications.

High values usually reflect elevated CRP and/or reduced lymphocytes, indicating active systemic inflammation, stress-mediated lymphocyte redistribution, or immune suppression. Common drivers include acute bacterial infection, tissue injury, surgery, autoimmune activity, or chronic inflammatory states. This pattern is associated with endothelial activation, insulin resistance, hypercoagulability, and higher short-term risk in settings like sepsis, cancer, and severe respiratory infections. Older age and late pregnancy tend to shift the ratio higher.

Drugs, vaccinations, exercise, and assay differences

Interpretation is influenced by age, pregnancy, obesity, smoking, and acute illness. Corticosteroids and chemotherapy lower lymphocytes; anti-inflammatory drugs can lower CRP. CRP assays (standard vs high-sensitivity), diurnal variation, recent vaccination or strenuous exercise, and hydration status can shift values. Severe liver dysfunction may blunt CRP, lowering the ratio despite inflammation. Reference ranges differ by laboratory.

A trajectory marker tied to vascular and infectious risk

CLR ties liver-driven innate responses to lymphocyte-mediated immunity, aligning with risks in cardiovascular disease, infections, and cancer. It complements CRP alone and other cell-based ratios, helping gauge trajectory and prognosis across systems.

FAQs

  • CLR testing measures CRP and lymphocyte count to calculate a ratio that reflects inflammatory signaling relative to adaptive immune cell availability.
  • It helps monitor inflammation and immune balance, track trends over time, and add context to cardiometabolic risk, training load, recovery, and overall resilience.
  • Establish a baseline when you feel well, then retest periodically or after significant lifestyle changes, illness, or intense training blocks to assess trends.
  • Infection, injury, strenuous exercise, adiposity, smoking, alcohol, oral health, sleep, stress, age, hormones (including menstrual phase and pregnancy), and medications (for example, statins, anti-inflammatories, and corticosteroids).
  • Fasting is not required. If you plan to test lipids or glucose at the same time, fasting may be helpful for those specific markers.
  • Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

    We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

    References

    1. He, X., Su, A., Xu, Y., Ma, D., Yang, G., Peng, Y., Guo, J., Hu, M., & Ma, Y. (2022). Prognostic role of lymphocyte-C-reactive protein ratio in colorectal cancer: A systematic review and meta-analysis. Frontiers in Oncology, 12, 905144. https://doi.org/10.3389/fonc.2022.905144
    2. Islam, M. M., Satici, M. O., & Eroglu, S. E. (2024). Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review. Turkish Journal of Emergency Medicine, 24(1), 8-19. https://doi.org/10.4103/tjem.tjem_198_23
    3. Yang, R., Chang, Q., Meng, X., Gao, N., & Wang, W. (2018). Prognostic value of systemic immune-inflammation index in cancer: A meta-analysis. Journal of Cancer, 9(18), 3295-3302. https://doi.org/10.7150/jca.25691
    4. Ridker, P. M. (2016). A test in context: High-sensitivity C-reactive protein. Journal of the American College of Cardiology, 67(6), 712-723. https://doi.org/10.1016/j.jacc.2015.11.037
    5. Brigden, M. L. (1999). Clinical utility of the erythrocyte sedimentation rate. American Family Physician, 60(5), 1443-1450. https://pubmed.ncbi.nlm.nih.gov/10524488/

    Built by the world’s top doctors and scientists

    Dr Anant Vinjamoori, MD

    Chief Longevity Officer, Superpower

    Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

    Learn more

    Dr Leigh Erin Connealy, MD

    Clinician & Founder of The Centre for New Medicine

    Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

    Learn more

    Dr Robert Lufkin

    UCLA Medical Professor, NYT Bestselling Author

    A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

    Learn more

    Dr Abe Malkin

    Founder & Medical Director of Concierge MD

    Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

    Learn more
    Membership slide 1
    Membership slide 1
    Membership slide 2
    Membership slide 3
    1 / 3

    Your membership starts here

    Annual 100+ biomarker panel

    Data dashboard and digital twin

    Upload past labs and connect wearables

    Personalized health protocol

    24/7 care team access

    AI companion for all health questions

    Marketplace with additional solutions

    $199

    /year*

    Billed annually

    HSA/ FSA eligible
    Cancel anytime
    Results in a week

    * Pricing may vary for members in New York and New Jersey